Discover 1,955 paid clinical trials in Plano, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,955
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
for
Diabetic Foot Ulcer
Location: Dallas TX, Houston TX, McAllen TX, O'Fallon IL,
Sponsor: Piomic Medical
Sex: All
Age: 22 - 70+
Code: NCT05758545
Recruiting
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
for
Locally Advanced Renal Cell Carcinoma
Location: Dallas TX, St Louis MO, Richmond VA
Sponsor: Qian Qin
Sex: All
Age: 18+
Code: NCT06794229
Phase 2, Recruiting
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
for
Atrial Fibrillation
Location: Dallas TX, Oklahoma City OK, Austin TX, Houston TX,
Sponsor: Johns Hopkins University
Sex: All
Age: 22 - 70+
Code: NCT05836987
Phase 3, Recruiting
VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration
for
Tetraplegia/Tetraparesis, Quadriplegia,
Location: Dallas TX
Sponsor: Neuralink Corp
Sex: All
Age: 22 - 70+
Code: NCT07224256
Recruiting
Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults
for
Invasive Candidiasis
Location: Dallas TX, Austin TX, Little Rock AR, St Louis MO,
Sponsor: Arkansas Children's Hospital Research Institute
Sex: All
Age: 0+
Code: NCT05763251
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Location: Fort Worth TX, Houston TX, San Antonio TX,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT06293898
Phase 1, Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Cancer, PDAC,
Location: Dallas TX, Longview TX, Lawrence KS, Kansas City MO,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07252232
Phase 3, Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Location: Grapevine TX, Tulsa OK, Sugar Land TX, San Antonio TX,
Sponsor: Eli Lilly and Company
Sex: All
Age: 6 - 17
Code: NCT05723198
Phase 3, Recruiting
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
for
Cytomegalovirus, Organ Transplant,
Location: Dallas TX, Boston MA
Sponsor: Camille N. Kotton, MD
Sex: All
Age: 18 - 70+
Code: NCT06958796
Recruiting
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
for
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer,
Location: Dallas TX, Fairfax VA
Sponsor: Hefei TG ImmunoPharma Co., Ltd.
Sex: All
Age: 18+
Code: NCT05746897
Phase 1, Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
for
Microvascular Inflammation
Location: Dallas TX, Houston TX, Kansas City KS, St Louis MO,
Sponsor: Biogen
Sex: All
Age: 18 - 70+
Code: NCT07219043
Phase 2, Recruiting
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
for
Advanced Hepatocellular Carcinoma
Location: Dallas TX, Houston TX, Chicago IL, Charlotte NC,
Sponsor: Iterion Therapeutics
Sex: All
Age: 18+
Code: NCT05797805
Phase 1, Phase 2, Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
for
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Location: Dallas TX, Oklahoma City OK, Chicago IL, Cincinnati OH,
Sponsor: CSL Behring
Sex: All
Age: 18+
Code: NCT07094087
Phase 3, Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)